Survival and prognostic features at the time of diagnosis in patients with MDS classified according to the refined WHO subtypes
| . | MDS . | RA . | 5q . | RARS . | RC + Dys . | RAEB I . | RAEB II . | MDS unclass . |
|---|---|---|---|---|---|---|---|---|
| Patients = N (%) | 333 | 76 (23) | 1 | 21 (6) | 96 (29) | 56 (17) | 82 (25) | 1 |
| IPSS (% patients) | ||||||||
| Low | 27 | 47 | 100 | 33 | 49 | 0 | 0 | |
| Intermediate-1 | 42 | 47 | 67 | 49 | 70 | 8 | 100 | |
| Intermediate-2 | 26 | 6 | 0 | 2 | 30 | 71 | ||
| High | 5 | 0 | 0 | 0 | 0 | 21 | ||
| Median survival (mo) | 43 | 63 | (NR) | 77 | 86 | 27 | 15 | (NR) |
| . | MDS . | RA . | 5q . | RARS . | RC + Dys . | RAEB I . | RAEB II . | MDS unclass . |
|---|---|---|---|---|---|---|---|---|
| Patients = N (%) | 333 | 76 (23) | 1 | 21 (6) | 96 (29) | 56 (17) | 82 (25) | 1 |
| IPSS (% patients) | ||||||||
| Low | 27 | 47 | 100 | 33 | 49 | 0 | 0 | |
| Intermediate-1 | 42 | 47 | 67 | 49 | 70 | 8 | 100 | |
| Intermediate-2 | 26 | 6 | 0 | 2 | 30 | 71 | ||
| High | 5 | 0 | 0 | 0 | 0 | 21 | ||
| Median survival (mo) | 43 | 63 | (NR) | 77 | 86 | 27 | 15 | (NR) |